Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤Q3 revenue $1.3 billion, up 29% year-over-year
- ➤Net income $162 million versus $200 million loss year-over-year
- ➤2026 revenue growth outlook raised to 15%-25% from up to 10%
- ➤Year-end 2026 cash outlook raised to $8.1-$8.3 billion
- ➤Intismeran plus KEYTRUDA cut melanoma recurrence or death risk 42%
Expert Statements
Stéphane Bancel, Chief Executive Officer of Moderna
“We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.”
Stéphane Bancel, Chief Executive Officer of Moderna
“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet.”
Stéphane Bancel, Chief Executive Officer of Moderna
“Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company.”
CAMBRIDGE, MA / ACCESS Newswire / November 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2026.
"We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma," said Stéphane Bancel, Chief Executive Officer of Moderna. "Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet. Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company."
Get started
Create a free account to read the full story.